MapLight Therapeutics (MPLT) vs Rezolute (RZLT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
MapLight Therapeutics is the larger company by market cap ($490.7 million vs $471.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MPLT | RZLT |
|---|---|---|
| Share price | $8.83 | $4.87 |
| Market cap | $490.73M | $471.04M |
| 1-day change | -3.50% | +4.96% |
| YTD return | -49.73% | +106.36% |
| 1-year return | — | -44.85% |
| 5-year return | — | -26.77% |
| EPS (TTM) | $-6.03 | $-0.75 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $40.43 | $11.46 |
| 52-week low | $8.71 | $1.07 |
| Distance from 52-week high | -78.16% | -57.49% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +200.57% | +101.23% |
| Average volume | 851.70K | 1.48M |
| Shares outstanding | 52.85M | 96.72M |
| Employees | 133 | 58 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About MapLight Therapeutics
MPLT stock →MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 133 employees
About Rezolute
RZLT stock →Rezolute, Inc., a late-stage rare disease company, focuses developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism (HI) in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody which is in Phase 3 clinical trial to treat tumor HI indication, as well as congenital HI.
Health Care · Biotechnology: Pharmaceutical Preparations · 58 employees
MPLT vs RZLT FAQ
Which is bigger, MapLight Therapeutics or Rezolute?
MapLight Therapeutics (MPLT) is larger, with a market capitalization of $490.73M compared with $471.04M for Rezolute (RZLT).
Are MapLight Therapeutics and Rezolute in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.